{"entity":{"id":"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021","kind":"paper","name":"Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma","aka":[],"tldr":"In a small trial combining PD-L1 and VEGF blockade, four in ten patients with previously treated peritoneal mesothelioma responded, with responses lasting well over a year, the first dedicated prospective evidence for immunotherapy in this rare disease.","summary":"Single-centre phase 2 study of 20 patients with advanced unresectable peritoneal mesothelioma progressing after platinum-pemetrexed, treated with atezolizumab and bevacizumab.\n\nObjective response was 40 percent with a median duration of response of 12.8 months, one-year progression-free survival 61 percent and one-year overall survival 85 percent; biomarker analyses linked response to epithelial-mesenchymal transition and immune features.","asOf":"2026-09-17","links":[{"label":"Cancer Discov 2021","url":"https://doi.org/10.1158/2159-8290.CD-21-0331"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/34261675/"}],"tags":[],"related":[],"cancers":["peritoneal-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-discovery"],"dependsOn":[],"notes":[],"journal":"Cancer Discovery","year":2021,"doi":"10.1158/2159-8290.CD-21-0331","pmid":"34261675","authors":"Raghav K, Liu S, Overman MJ, et al.","paperType":"observational","findings":["Objective response 40 percent; median duration of response 12.8 months.","One-year overall survival 85 percent."],"whatItMeans":"Immunotherapy combinations, largely extrapolated from pleural trials, now have direct supporting data in peritoneal mesothelioma and are used after or instead of chemotherapy in unresectable disease.","caveats":["Twenty patients at a single centre; no comparator."],"changedPractice":false,"participants":20},"route":"/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/","neighbours":{"cancer":[{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"journal":[{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/"}]}}